Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
Would you consider the addition of trastuzumab to carboplatin/paclitaxel for an advanced uterine carcinosarcoma that stains HER2 IHC 3+ in the carcinomatous components but IHC 0 in the sarcomatous regions?
Related Questions
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
Following surgical staging, what adjuvant therapy would you recommend for stage IB grade 3 endometrioid endometrial carcinoma with +LVSI?
Do you offer resection of oligometastatic disease for patients with recurrent uterine serous carcinoma within the pelvis following initial treatment with adjuvant chemotherapy and vaginal cuff brachytherapy?
Is it ever acceptable to treat low pelvis (vs. whole pelvis) for an early vaginal recurrence of endometrial cancer?
When do you consider adjuvant chemotherapy and/or RT for stage I-III high-grade uterine sarcomas s/p resection?
How would you approach the management of a women who was incidentally found to have a deeply invasive low-grade endometrial carcinoma after she underwent a supracervical hysterectomy with placement of mesh for uterine prolapse?
Would you offer pelvic radiation in a patient with Stage IIIC endometrial cancer who has Crohn's disease and a permanent ileostomy?
Do you include trastuzumab in the treatment regimen of patients with advanced stage HER2+ endometrial cancer that is NOT serous or carcinosarcoma?
When treating endometrial cancer patients with a combination of chemotherapy and vaginal cuff brachytherapy, when do you deliver cuff brachy?
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?